Biotechnology company Can-Fite BioPharma Ltd (NYSE American:CANF) (TASE:CFBI) disclosed on Friday that its net loss was USD7.84m for the nine months ended 30 September 2019.
This reflects a dip in earnings when compared with a lower net loss of USD3.14m for the same period in 2018.
Revenues of USD1.84m were generated for the nine months ended 30 September 2019, down from revenues of USD3.53m for the same period of 2018, mainly due to the recognition of advance payment under the distribution agreement with CMS Medical.
Research and development (R&D) expenses of USD7.01m were recorded for the nine months ended 30 September 2019, a rise over R&D of USD4.05m for the same period of 2018.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government